Oral Anti-Cancer Drug (OACD) Fees
OACDs are billed using the National Drug Code (NDC). Such drug fees are subject to change on a quarterly basis. Currently, these drugs meet the requirements for coverage under the Omnibus Budget Reconciliation Act of 1993 (OBRA '93). They are not assigned HCPCS codes.
Lists contain Drug Manufacturers, Strength of Drug, NDC, and Allowable based on Average Sales Price (ASP)
Year | Quarter |
---|---|
2025 | Quarter 1 - Updated December 23, 2024 |
2024 |
Quarter 4 - Updated September 25, 2024 |
2023 |
Quarter 4 - Updated September 21, 2023 |
2022 |
Quarter 4 - Updated September 27, 2022 |
2021 |
Quarter 4 - Updated September 20, 2021 |
2020 |
Quarter 4 - Updated September 22, 2020 |
Note: This information is provided as a service to our customers. While every effort is made to ensure the accuracy of this information up to our publication deadline, we are not responsible for any errors or subsequent changes. There is no eligibility guarantee for reimbursement based on using this information. Reimbursement is based on factors including, but not limited to: disease diagnosis, medical necessity for the DMEPOS item and the Medicare program coverage guidelines.
Inclusion or exclusion of a fee schedule amount for an item or service does not imply any health insurance coverage.
Quarter 1: January 1 - March 31
Quarter 2: April 1 - June 30
Quarter 3: July 1 - September 30
Quarter 4: October 1 - December 31
If older files are needed, contact the PDAC Contact Center.
Oral Anti-Cancer Drug (OACD) Fees Articles
There are no articles under this category. |